NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.
Corradi, M.; Chrystyn, Henry; Cosio, Borja G.et al.
2014 • In Expert Opinion on Drug Delivery, 11 (9), p. 1497-506
[en] INTRODUCTION: Airway inflammation and remodelling in asthma occur in the large airways and also in the small airways. The small airways are those < 2 mm in diameter and are significant sites of chronic asthmatic inflammation. It is important, therefore, to target the small as well as the large airways in any strategy for effective treatment of this disease. AREAS COVERED: The present review deals with the recently developed fixed dose drug combination of beclometasone dipropionate/formoterol fumarate that emits extrafine particles when delivered from an innovative dry powder inhaler (DPI), NEXThaler(R). The aim is to present the technical and clinical aspects of aerosolized drug delivery to the lungs. EXPERT OPINION: The data show that the NEXThaler DPI is an efficient device for the management of persistent asthma. The evaluation of the inhalation profiles through the NEXThaler DPI demonstrates that device activation and consistent dose delivery occurs at patient achievable inhalation flow rates, and supports the broad utility of the NEXThaler DPI in patients with asthma. Overall, all the effectiveness, efficiency and satisfaction outcomes demonstrate the NEXThaler DPI is easy to use.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Corradi, M.
Chrystyn, Henry
Cosio, Borja G.
Pirozynski, Michal
Loukides, Stelios
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Spinola, Monica
Usmani, Omar S.
Language :
English
Title :
NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.
Un erratum a été publié. Il est joint à cette fiche. Voici sa référence : Expert Opin Drug Deliv. 2014 Nov;11(11):1827. URL : http://informahealthcare.com/doi/pdf/10.1517/17425247.2014.976738.
Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404-6
Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med 2012;44:146-56
Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: Direct measurement of intrabronchial pressure. J Appl Physiol 1992;72:1016-23
Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95:703-19
Macklem PT. The physiology of small airways. Am J Respir Crit Care Med 1998;157:S181-3
Takeda T, Oga T, Niimi A, et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010;80:120-6
Kaminsky DA, Irvin CG, Gurka DA, et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995;152:1784-90
Kraft M, Djukanovic R, Torvik J, et al. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 1995 107 162S
Kraft M, Djukanovic R, Torvik J, et al. Evaluation of airway inflammation by endobronchial and transbronchial biopsy in nocturnal and nonnocturnal asthma. Chest 1995;107:162S 9. Anderson WJ, Zajda E, Lipworth BJ. Are we overlooking persistent small airways. dysfunction in community-managed asthma?. Ann Allergy Asthma Immunol 2012;109(3):185-9
Perez T, Chanez P, Dusser D, et al. Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. Respir Med 2013;107:1667-74
Yamaguchi M, Niimi A, Ueda T, et al. Effect of inhaled corticosteroids on small airways in asthma: Investigation using impulse oscillometry. Pulm Pharmacol Ther 2009;22:326-32
Farah CS, King GG, Brown NJ, et al. The role of the small airways in the clinical expression of asthma in adults. J Allergy Clin Immunol 2012;129:381-7
Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: Major challenges for pulmonary drug delivery. Expert Opin Drug Deliv 2014;11(3):365-78
Hesselink AE, Penninx BW, Wijnhoven HA, et al. Determinants of an incorrect inhalation technique in patients with asthma or COPD. Scan J Prim Health Care 2001;19:255-60
Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 1986;41:118-24
Goren A, Noviski N, Avital A, et al. Assessment of the ability of young children to use a powder inhaler device (Turbuhaler). Pediatr Pulmonol 1994;18:77-80
Bryant L, Bang C, Chew C, et al. Adequacy of inhaler technique used by people with asthma or chronic obstructive pulmonary disease. J Prim Health Care 2013;5:191-8
Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Respir Care 2005;50:1360-74
Ninane V, Brusselle GG, Louis R, et al. Usage of inhalation Devices in asthma and chronic obstructive pulmonary disease: A Delphi consensus statement. Expert Opin Drug Deliv 2014;11:313-23
Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-Agonist particle size. Am J Respir Crit Care Med 2005;172:1497-504
Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012;108:195-200
Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 2001;95:720-7
Paggiaro P, Nicolini G, Papi A. Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. Expert Rev Respir Med 2008;2:161-6
Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations. J Asthma Allergy 2013;6:11-21
Dekhuijzen PN, Vincken W, Virchow JC, et al. Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach. Respir Med 2013;107:1817-21
Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-31
Newhouse MT, Nantel NP, Chambers CB, et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metereddose inhaler, even at low flow rates. Chest 1995;115:952-6
Pasquali I, Brambilla G, Long E, et al. A visualization study for the aerosol generation in NEXThaler. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14-18; 2012;Chicago, Poster: M1150
Mariotti F, Sergio F, Acerbi D, et al. Lung deposition of the extra-fine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI- in healthy subjects, asthmatic and COPD patients. Presented at the European Respiratory Society 21st Annual Congress; 24 - 28 September 2011; Amsterdam, The Netherlands
Mitchell JP, Nagel MW. Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations. J Aerosol Med 2003;16:341-77
De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010;23:137-48
Sergio F, Francisco C, Muraro A, et al. Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy. Presented at the European Respiratory Society 22st Annual Congress; 1 - 5 September 2012; Vienna, Austria
Zuccaro F, Sergio F, Petruzzelli S, et al. Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients. Presented at the European Respiratory Society 20th Annual Congress 18-22 September 2010; Barcelona, Spain. Eur Respir J 2010;36(Suppl 54):829s
Scuri M, Alfieri V, Giorgio A, et al. Measurement of the inhalation profile through a novel dry powder inhaler (NEXThaler) in asthmatic patients using acoustic monitoring. Am J Respir Crit Care Med 2013;187:A1931
EMEA/CHMP/QWP/49313/2005corr. (2005): Committee For Medicinal Products For Human Use (CHMP). Guideline on the pharmaceutical quality of inhalation and nasal products
Price D, Thomas M, Mitchell G, Niziol C. Improvement of asthma control with a breath-Actuated pressurised metred dose inhaler (BAI): A prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-Actuated device. Respir Med 2003;97:12-19
Voshaar T, Spinola M, Linnane P, et al. Comparing usability of NEXThaler with other inhaled corticosteroid/long-Acting beta2-Agonist fixed combination Dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Deliv 2013; doi: 10.1089/jamp.2013.1086
Anderson P. Patient preference for and satisfaction of inhaler devices. Eur Respir Rev 2005;14:109-16.
